Aska buys option to commercialize Pieris' potential EPO rival in Japan
Aska Pharmaceutical Co. Ltd has bought an option to commercialize Pieris Pharmaceuticals’ anaemia candidate and EPO rival, PRS-080, in Japan.
Aska Pharmaceutical Co. Ltd has bought an option to commercialize Pieris Pharmaceuticals’ anaemia candidate and EPO rival, PRS-080, in Japan.
Fujifilm has separated its biopharmaceutical contracting business in an effort to triple its revenues to ¥100bn ($890m) within seven years.
A Californian manufacturing facility to support clinical development of a haemophilia A gene therapy will be completed this year, says BioMarin.